Pharma News

Department of Defense Awards Emergent BioSolutions With $235.8 Million Contract for Anthrax Vaccine

The BioThrax vaccine is indicated for active immunization to prevent anthrax disease caused by Bacillus anthracis in individuals aged 18 through 65 years.

Source link
#Department #Defense #Awards #Emergent #BioSolutions #Million #Contract #Anthrax #Vaccine

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *